Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients.

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Unicancer

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

22 Oct 2025 → ongoing

Decision date (initial)

2025-08-11

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

AstraZeneca for Phase II · PHRC_K2022 for Phase III : INCa PHRC

External identifiers

EU CT number

2024-514912-28-00

ClinicalTrials.gov

NCT06904170

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

Phase II part: To compare efficacy between the two treatment arms in terms of Objective Response Rate (ORR) according to RECIST v1.1.
Phase III part: To compare efficacy between the two treatment arms in terms of Overall Survival (OS).

Secondary objectives 3

1. To assess safety of the combination of immune therapy and HAIC
2. To compare efficacy between the two treatment arms in terms of: o Progression-Free Survival (PFS) according to RECIST 1.1 and mRECIST o ORR according to RECIST 1.1 (in phase III part) o Overall Survival (OS) (in phase II part)
3. To compare health-related quality-of-life (HR-QoL) throughout the study

Conditions and MedDRA coding

Patients with hepatocellular carcinoma with high tumor burden.

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 15

1. Age ≥18 years old,
2. Patient presenting with hepatocellular carcinoma (HCC), advanced or unresectable, diagnosed either by histological or radiological criteria as described by EASL criteria, if no biopsy could be performed safely.
3. High-tumor burden, defined as at least one of the three criteria: (i) Vp4 PVTT, (ii) Vp3 PVTT with bilobar tumoral involvement and/or (iii) liver involvement >50% (as assessed by the investigator). Extra-hepatic spread is allowed.
4. Child-Pugh A liver function stage B or stage C according to Barcelona Clinic Liver Cancer classification (BCLC) of hepatocarcinoma
5. Performance status Eastern Cooperative Oncology Group (ECOG) 0 to 1
6. Must have a life expectancy of at least 12 weeks
7. Body weight >30 kg
8. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion (TL) at baseline. Tumor assessment by computed tomography (CT) scan or magnetic resonance imaging (MRI) must be performed within 28 days prior to randomization
9. Adequate organ and marrow function as indicated by the following laboratory values a. Haemoglobin ≥ 9 g/dL, b. Platelet count ≥100 × 10^9/L, c. Absolute neutrophil count (ANC ≥1.0 × 109 /L) d. creatinine clearance > 40 mL/min (according to Cockcroft or MDRD formula) e. AST (SGOT)/ALT (SGPT) ≤5x ULN f. Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). g. International normalised ratio (INR) < 2.3 h. Potassium < 3,5 mEq/L (< 3,5 mmol/L) i. Magnesium < 1,8 mg/dL (< 0,70 mmol/L) j. Total serum calcium concentration < 8.8 mg/dL (< 2.20 mmol/L)
10. Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥90 days after the last dose of durvalumab monotherapy or durvalumab and tremelimumab combination therapy,, for at least 15 months after the end of the treatment with oxaliplatin, for at least 6 months after the end of the treatment with gemcitabine, and have a negative urine or serum pregnancy test ≤7 days of first dose of study drug. In case of a urine pregnancy test, it must be a highly sensitive urine pregnancy test.
11. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥90 after the last dose of durvalumab monotherapy or durvalumab and tremelimumab combination therapy, for at least 12 months after the end of the treatment with oxaliplatin, for at least 3 months after the end of the treatment with gemcitabine. A sterile male is defined as one for whom azoospermia has been previously demonstrated in a semen sample examination as definitive evidence of infertility. Males with known “low sperm counts” (consistent with “sub-fertility”) are not to be considered sterile for purposes of this study.
12. Men and women patients must consent to not donate or bank sperm or ova during treatment and for 180 days after treatment stop
13. Patients must have provided consent for the study by signing and dating a written informed consent form prior to any study specific procedures, sampling, or analyses. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent
14. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
15. Patient affiliated to a social security regimen

Exclusion criteria 27

1. Previous systemic treatment (either immunotherapy, anti-angiogenics, chemotherapy, or any combination thereof)
2. History of leptomeningeal carcinomatosis
3. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
4. Known to have been tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
5. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea
6. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)
7. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: ➢ Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) ➢ Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent ➢ Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
8. Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug
9. History of allogenic organ transplantation, or patient with intent for transplantation
10. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study drug. Note: Local surgery of isolated lesions for palliative intent is acceptable, patient must not be eligible for liver transplantation
11. Prior malignancy active within the previous 5 years of inclusion except for locally curable cancers considered cured or successfully resected, such as basal or squamous cell skin cancers, superficial bladder cancer, or gastric cancers, or carcinoma in situ of the prostate, cervix, or breast carcinomas. Any oncological concomitant treatment is not allowed during the treatment period. a) Radiotherapy within 28 days prior to the first dose of study drug
12. Previous treatment with hepatic arterial infusion of chemotherapy
13. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
14. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or180 days after the last dose of durvalumab and tremelimumab combination therapy.
15. Participation in another therapeutic trial within the 30 days prior to study inclusion
16. Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
17. Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
18. Patients deprived of their liberty or under protective custody or guardianship
19. Patients unable to adhere to the protocol for geographical, social, or psychological reasons or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
20. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
21. History of hepatic encephalopathy within the past 6 months or requirement for medications to prevent or control encephalopathy (eg, no lactulose, rifaximin, etc if used for purposes of hepatic encephalopathy).
22. Active or prior documented gastrointestinal bleeding (GI; eg, esophageal varices or ulcer bleeding) within the past 6 months. Note: For participants with a history of GI bleeding greater than 6 months or assessed as high risk for esophageal varices by the investigator, including main trunk portal vein thrombosis, a recent endoscopy within 3 months of enrolment and adequate endoscopic therapy according to institutional standards is required.
23. Any unresolved toxicity NCI CTCAE grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria a) Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. b) Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
24. Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non–cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
25. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: a) Patients with vitiligo or alopecia b) Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement c) Any chronic skin condition that does not require systemic therapy d) Patients without active disease in the last 5 years may be included but only after consultation with the study physician e) Patients with celiac disease controlled by diet alone
26. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases
27. Ionic disorders as: a. Potassium < 3,5 mEq/L (< 3,5 mmol/L) b. Magnesium < 1,8 mg/dL (< 0,70 mmol/L) c. Total serum calcium concentration < 8.8 mg/dL (< 2.20 mmol/L)

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. For the Phase II study: Objective Response Rate (ORR), defined as the proportion of patients with Complete Response (CR) or Partial Response (PR) as best response according to RECIST 1.1 by investigator evaluation, within the time frame from randomization to 6-month follow-up.
2. For the Phase III study: Overall survival (OS) defined as the time between randomization and death from any cause. A patient who is alive or lost to follow-up at the time of the analysis will be censored at the date of the last protocol visit actually carried out by the patient.

Secondary endpoints 5

1. Safety of the combination evaluated by: o Frequency of limiting toxicity (LT) occurring during the combination phase (i.e. the first 12 weeks). A LT is defined as any toxicity related to the experimental drug, that require definitive treatment discontinuation of any of the study intervention (HAIC or Durvalumab or Tremelimumab). o Frequency and severity of treatment-related adverse Events (AEs) as per NCI-CTCAE v5.0, until 30 days after the end of any study treatment.
2. Progression-Free survival (PFS), defined as the time between the date of randomization and the date of first progression or death, whichever occurs first. Progression will be defined according to RECIST v1.1 and mRECIST criteria. A patient who is alive and not progressive at the time of the analysis, or lost to follow-up, will be censored at the date of the last protocol visit actually carried out by the patient.
3. In phase II part: Overall survival (OS) defined as the time between randomization and death from any cause. A patient who is alive or lost to follow-up at the time of the analysis will be censored at the date of the last protocol visit actually carried out by the patient.
4. In phase III part: Objective Response Rate (ORR), defined as the proportion of patients with Complete Response (CR) or Partial Response (PR) as best response according to RECIST 1.1.
5. Quality of life according to EORTC QLQ-C30 and HCC-18, evaluated at baseline (before randomization), and every two months until disease progression or study end.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 10

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Unicancer

Sponsor organisation

Unicancer

Address

101 Rue De Tolbiac

City

Paris Cedex 13

Postcode

75654

Country

France

Scientific contact point

Organisation

Unicancer

Contact name

Nourredine Nourredine AIT RAHMOUNE

Public contact point

Organisation

Unicancer

Contact name

Nourredine Nourredine AIT RAHMOUNE

Locations

1 EU/EEA country · 13 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 13 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications